Capturing Post-Approval Safety and Efficacy Data on Cell and Gene Therapy Products
The FDA’s Center for Biologics Evaluation and Research (CBER) Office of Therapeutic Products (OTP) is hosting a virtual public listening meeting on 27 April 2023 to solicit input on methods